Nausea and Vomiting: Common Causes

Introduction

Nausea and vomiting represent a frequent and distressing symptom complex encountered in diverse clinical settings. These phenomena are manifestations of a coordinated neurophysiological response that serves to eliminate harmful substances from the gastrointestinal tract. Historically, the description of emetic episodes dates back to ancient medical texts, yet a comprehensive understanding has emerged only in the last century through advances in neuroanatomy and pharmacology. The relevance to pharmacology is multifaceted: the symptom is a frequent adverse effect of many therapeutic agents, a clinical endpoint for evaluating drug efficacy, and a target for antiemetic drug development. The following learning objectives are addressed in this chapter:

• Define nausea and vomiting and outline their physiological underpinnings.
• Identify the major etiological categories contributing to these symptoms.
• Describe the neurochemical pathways implicated in the emetic response.
• Discuss the clinical implications of nausea and vomiting for drug therapy selection.
• Apply knowledge of causative factors to management strategies in clinical scenarios.

Fundamental Principles

Core Concepts and Definitions

Nausea is a subjective sensation of queasiness that may or may not progress to the expulsion of gastric contents. Vomiting is the forceful expulsion of the contents of the stomach through the oral cavity, mediated by a coordinated contraction of abdominal musculature and the diaphragm. The two phenomena are closely linked but can occur independently. The emetic reflex arc encompasses afferent pathways, central integration centers, and efferent outputs that culminate in the act of vomiting.

Theoretical Foundations

Central to the emetic response are the vomiting center located in the medullary reticular formation and the area postrema, a circumventricular organ devoid of a blood–brain barrier. Peripheral stimuli are conveyed via the vagus nerve, glossopharyngeal nerve, and spinal afferents to these central sites. The integration of signals occurs within the nucleus tractus solitarius, which then projects to the dorsal motor nucleus of the vagus and the nucleus ambiguus, orchestrating the motor patterns necessary for emesis.

Key Terminology

• Area postrema: a chemoreceptor trigger zone that detects circulating emetic substances.
• Chemoreceptor trigger zone (CTZ): a region of the brainstem sensitive to circulating neurotransmitters and drugs.
• Gastrointestinal (GI) tract: the pathway from the esophagus to the anus; sites of many emetic stimuli.
• Peripheral chemoreceptors: receptors in the GI tract and vestibular system that detect noxious stimuli.
• Central chemoreceptors: receptors in the medullary reticular formation that respond to neurotransmitters.
• Anti-emetic: a drug that reduces or prevents nausea and vomiting.

Detailed Explanation

Mechanisms and Processes

The emetic reflex can be triggered by a variety of stimuli: toxic ingestions, metabolic disturbances, central nervous system (CNS) lesions, vestibular perturbations, pharmacological agents, and psychological factors. The convergence of these stimuli occurs at several key nodes:

1. Peripheral Input: Nerve endings in the GI tract, inner ear, and ocular structures sense irritants and send afferent signals via the vagus and glossopharyngeal nerves.
2. Central Integration: Signals reach the nucleus tractus solitarius and the area postrema, where neurotransmitters such as dopamine (D2 receptors), serotonin (5-HT3 receptors), histamine (H1 receptors), and acetylcholine (muscarinic receptors) modulate the activity of the vomiting center.
3. Efferent Output: The vomiting center initiates a cascade involving the diaphragm, abdominal muscles, and pharyngeal constrictors to expel gastric contents.

The neurochemical pathways can be summarized by the following relation, illustrating the interplay of neurotransmitter concentrations and receptor activation:
C_neuro = Σ (Dose of neurotransmitter × Affinity factor)
where C_neuro denotes the effective concentration influencing the vomiting center.

Mathematical Relationships and Models

Pharmacokinetic models aid in understanding drug-induced nausea by predicting peak plasma concentrations (C_max) and half-lives (t_1/2). For instance, the concentration of a drug at time t can be expressed as:
C(t) = C₀ × e^-kt
where C₀ is the initial concentration and k is the elimination rate constant. A drug with a high C_max relative to its therapeutic threshold is more likely to activate the CTZ and provoke emesis.

Factors Affecting the Process

• Drug properties: lipophilicity, molecular weight, and affinity for emetic receptors.
• Patient characteristics: age, sex, genetic polymorphisms in metabolizing enzymes, and prior history of motion sickness.
• Co-administered medications: drugs that potentiate or antagonize emetic pathways.
• Physiological state: pregnancy, fasting, and hydration status.

Clinical Significance

Relevance to Drug Therapy

Drug-induced nausea is a common dose-limiting adverse effect. Antiemetic agents target specific neurotransmitter systems: 5‑hydroxytryptamine (5‑HT3) antagonists, dopamine (D2) antagonists, histamine (H1) antagonists, and neurokinin-1 (NK1) antagonists. Understanding the underlying mechanism is essential for selecting the most appropriate antiemetic in a given clinical context.

Practical Applications

Clinicians routinely assess the risk of nausea and vomiting when prescribing medications with high emetic potential, such as chemotherapeutic agents, opioids, and certain antibiotics. Prophylactic antiemetic regimens are often required to mitigate these effects and preserve patient adherence.

Clinical Examples

• High-dose cisplatin administration is frequently associated with acute, delayed, and anticipatory nausea and vomiting, necessitating a multi‑modal antiemetic protocol.
• Opioid therapy for chronic pain can lead to a dose-dependent increase in nausea, managed by co‑prescribing a D2 antagonist.
• Post‑operative patients may develop nausea due to anesthetic agents and the body’s response to surgical stress.

Clinical Applications/Examples

Case Scenario 1 – Chemotherapy‑Induced Nausea

A 55‑year‑old woman receives a cisplatin‑based regimen for ovarian cancer. She reports intense nausea within 24 hours post‑infusion. The clinical team initiates a prophylactic antiemetic regimen comprising a 5‑HT3 antagonist, a D2 antagonist, and an NK1 antagonist. Over the subsequent cycles, the frequency and severity of emesis decrease markedly, illustrating the importance of multi‑targeted therapy.

Case Scenario 2 – Post‑operative Nausea and Vomiting (PONV)

A 42‑year‑old male undergoes laparoscopic cholecystectomy. He experiences nausea in the recovery room that progresses to vomiting within 12 hours. The anesthetic plan included propofol and fentanyl; both are known to increase emetic risk. In response, the team administered a prophylactic D2 antagonist and a 5‑HT3 antagonist post‑operatively. The patient reported significant symptom relief and was discharged without further episodes.

Case Scenario 3 – Vestibular‑Induced Nausea

A 30‑year‑old woman presents with dizziness and nausea after a prolonged airplane flight. Examination reveals vestibular dysfunction, and her symptoms resolve with a short course of a D2 antagonist. This case underscores the role of the vestibular system as a peripheral trigger of nausea.

Problem‑Solving Approaches

• Identify the likely trigger: drug, metabolic disturbance, central lesion, or vestibular irritation.
• Assess the severity and timing of nausea to classify it as acute, delayed, or anticipatory.
• Select an antiemetic based on the predominant neurotransmitter pathway involved.
• Consider drug interactions and patient-specific factors that may alter drug metabolism.
• Reassess and adjust therapy after 24–48 hours to ensure optimal control.

Summary / Key Points

• Nausea and vomiting arise from a complex neurophysiological reflex involving peripheral and central chemoreceptors.
• Common etiological categories include drug-induced, metabolic, central nervous system, vestibular, and psychological triggers.
• The area postrema and vomiting center mediate the integration of signals, with key neurotransmitters such as dopamine, serotonin, histamine, and acetylcholine playing central roles.
• Pharmacokinetic parameters (C_max, t_1/2) influence the likelihood of drug-induced emesis.
• Multimodal antiemetic therapy targeting multiple neurotransmitter systems is most effective for high‑risk clinical situations such as chemotherapy and postoperative care.
• Clinical decision-making should incorporate patient factors, drug properties, and potential interactions to tailor antiemetic regimens.
• Recognition of nausea as an early warning sign of systemic disease or drug toxicity can prompt timely intervention.

References

1. Porter RS. The Merck Manual of Diagnosis and Therapy. 20th ed. Kenilworth, NJ: Merck Sharp & Dohme Corp; 2018.
2. Bennett PN, Brown MJ, Sharma P. Clinical Pharmacology. 12th ed. Edinburgh: Elsevier; 2019.
3. Waller DG, Sampson AP. Medical Pharmacology and Therapeutics. 6th ed. Edinburgh: Elsevier; 2022.
4. Feather A, Randall D, Waterhouse M. Kumar and Clark's Clinical Medicine. 10th ed. London: Elsevier; 2020.
5. Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. 21st ed. New York: McGraw-Hill Education; 2022.
6. Ralston SH, Penman ID, Strachan MWJ, Hobson RP. Davidson's Principles and Practice of Medicine. 24th ed. Edinburgh: Elsevier; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.